当前位置: X-MOL 学术Clin. Epigenet. › 论文详情
Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)
Validation of an epigenetic field of susceptibility to detect significant prostate cancer from non-tumor biopsies.
Clinical Epigenetics ( IF 5.7 ) Pub Date : 2019-11-28 , DOI: 10.1186/s13148-019-0771-5
Bing Yang 1 , Tyler Etheridge 1 , Johnathon McCormick 1 , Adam Schultz 1 , Tariq A Khemees 1, 2 , Nathan Damaschke 1 , Glen Leverson 1 , Kaitlin Woo 1 , Geoffrey A Sonn 3 , Eric A Klein 4 , Mike Fumo 5 , Wei Huang 1, 6 , David F Jarrard 1, 2, 6, 7
Affiliation  

BACKGROUND An epigenetic field of cancer susceptibility exists for prostate cancer (PC) that gives rise to multifocal disease in the peripheral prostate. In previous work, genome-wide DNA methylation profiling identified altered regions in the normal prostate tissue of men with PC. In the current multicenter study, we examined the predictive strength of a panel of loci to detect cancer presence and grade in patients with negative biopsy tissue. RESULTS Four centers contributed benign prostate biopsy tissues blocks from 129 subjects that were either tumor associated (TA, Grade Group [GG] ≥ 2, n = 77) or non-tumor associated (NTA, n = 52). Biopsies were analyzed using pyrosequencing for DNA methylation encompassing CpG loci near CAV1, EVX1, FGF1, NCR2, PLA2G16, and SPAG4 and methylation differences were detected within all gene regions (p < 0.05). A multiplex regression model for biomarker performance incorporating a gene combination discriminated TA from NTA tissues (area under the curve [AUC] 0.747, p = 0.004). A multiplex model incorporating all the above genes and clinical information (PSA, age) identified patients with GG ≥ 2 PC (AUC 0.815, p < 0.0001). In patients with cancer, increased variation in gene methylation levels occurs between biopsies across the prostate. CONCLUSIONS A widespread epigenetic field defect is utilized to detect GG ≥ 2 PC in patients with histologically negative biopsies. These alterations in non-tumor cells display increased heterogeneity of methylation extent and are spatially distant from tumor foci. These findings have the potential to decrease the need for repeated prostate biopsy.

中文翻译:

验证易感性的表观遗传学领域,以从非肿瘤活检中检测出重要的前列腺癌。

背景技术存在对于前列腺癌(PC)的癌症易感性的表观遗传学领域,其在周围前列腺中引起多灶性疾病。在先前的工作中,全基因组DNA甲基化图谱鉴定了PC男性男性正常前列腺组织中的改变区域。在当前的多中心研究中,我们检查了一组位点的预测强度,以检测活检组织阴性的患者中癌症的存在和等级。结果四个中心贡献了来自129例与肿瘤相关(TA,等级组[GG]≥2,n = 77)或与非肿瘤相关(NTA,n = 52)的前列腺良性活检组织。使用焦磷酸测序对活检进行了分析,分析了CAV1,EVX1,FGF1,NCR2,PLA2G16和SPAG4附近CpG位点的DNA甲基化,并在所有基因区域内检测到甲基化差异(p <0。05)。生物标志物性能的多元回归模型,其中包含从NTA组织中区分TA的基因组合(曲线下面积[AUC] 0.747,p = 0.004)。包含以上所有基因和临床信息(PSA,年龄)的多元模型确定了GG≥2 PC的患者(AUC 0.815,p <0.0001)。在患有癌症的患者中,前列腺穿刺活检之间基因甲基化水平的变化增加。结论广泛的表观遗传缺陷被用于检测组织学阴性的活检患者的GG≥2 PC。非肿瘤细胞中的这些变化显示出甲基化程度的增加的异质性,并且在空间上远离肿瘤灶。这些发现有可能减少重复进行前列腺活检的需要。生物标志物性能的多元回归模型,其中包含从NTA组织中区分TA的基因组合(曲线下面积[AUC] 0.747,p = 0.004)。包含以上所有基因和临床信息(PSA,年龄)的多元模型确定了GG≥2 PC的患者(AUC 0.815,p <0.0001)。在患有癌症的患者中,前列腺穿刺活检之间基因甲基化水平的变化增加。结论广泛的表观遗传缺陷被用于检测组织学阴性的活检患者的GG≥2 PC。非肿瘤细胞中的这些变化显示出甲基化程度的增加的异质性,并且在空间上远离肿瘤灶。这些发现有可能减少重复进行前列腺活检的需要。生物标志物性能的多元回归模型,其中包含从NTA组织中区分TA的基因组合(曲线下面积[AUC] 0.747,p = 0.004)。包含以上所有基因和临床信息(PSA,年龄)的多元模型确定了GG≥2 PC的患者(AUC 0.815,p <0.0001)。在患有癌症的患者中,前列腺穿刺活检之间基因甲基化水平的变化增加。结论广泛的表观遗传缺陷被用于检测组织学阴性的活检患者的GG≥2 PC。非肿瘤细胞中的这些变化显示出甲基化程度的增加的异质性,并且在空间上远离肿瘤灶。这些发现有可能减少重复进行前列腺活检的需要。
更新日期:2019-11-28
down
wechat
bug